BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

ASH 2024

More Like This

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024